Sermorelin ODT
The needle-free route to sermorelin — offered honestly, including what we can't tell you about it.
- Sleep quality — the growth hormone axis is most active during deep sleep, and sleep is the outcome patients most often report first
- Recovery — how you feel after training, travel or physical work
- Energy through the day
- Body composition, alongside resistance training and adequate protein rather than instead of them
Every one of those is a "may help support," not a promise. Individual response varies substantially, and the variation is larger for a route with no established pharmacokinetics.
- Live visit with a licensed clinician
- Medication delivered to your home, if prescribed
- Medication included in the price, with no separate medication fee
- Subscription, cancel anytime
Indicative price · confirmed after eligibility · prescription treatment
What sermorelin is, and what compounded means here
Sermorelin is a 29-amino-acid peptide. It is the first 29 amino acids of your own growth hormone-releasing hormone — the shortest fragment that still does the job GHRH does. Its mechanism is a signal, not a substitute: it prompts the pituitary to release more of the growth hormone your body already makes, on your body's own rhythm and within your body's own feedback loops.
That distinction is the whole reason sermorelin exists as a category. Injected growth hormone overrides the system. A GHRH analogue asks it to work harder, and the pituitary's own regulation stays in place — which is why the response tends to be more modest and more variable than people expect from the marketing.
Sermorelin is not new and not experimental. It was FDA-approved in 1997 under the brand name Geref, for growth hormone deficiency in children. It was discontinued in the United States in 2008 for commercial reasons, not safety ones — the market was small and growth hormone had taken it. Since then it has been available only through compounding pharmacies.
Sermorelin ODT is sermorelin acetate prepared as an oral dissolving tablet by a licensed compounding pharmacy. A compounded medication is prepared for an individual patient, it is not an FDA-approved product, and it has not been through FDA review for safety, efficacy or manufacturing for this use. That is true of sermorelin in every form sold in the United States today, ours included, and any provider who implies otherwise is misleading you.
How it works here
Every plan follows one path. Each step feeds the next. See the Peptide Therapy approach.
- 01
Measure
We baseline your labs, history, and goals.
- 02
Plan
A clinician decides whether this fits — and what else might serve you.
- 03
Act
If appropriate, you start with clear guidance and high-touch support.
- 04
Track
We monitor how you respond on a defined cadence.
- 05
Adjust
Protocols are refined over time. Guided care, not a kit in the mail.
Where sermorelin sits in the regulatory picture
It is worth being specific about where sermorelin sits in the current regulatory picture, because the peptide category has been moving.
In April 2026 the FDA removed twelve peptide substances from Category 2 of its interim 503A bulks list, following withdrawal of the nominations. Removal from Category 2 did not make those substances compoundable. Sermorelin was not among the twelve, and it is not in the same regulatory position as the peptides that were restricted. ACT 2 Health does not offer any of them.
We are telling you this because the peptide market is full of pages that either ignore regulation entirely or imply an approval that does not exist. Sermorelin's actual position — a formerly approved drug, withdrawn for business reasons, now compounded — is defensible on its own. It does not need to be dressed up.
The honest part: the ODT route specifically
This is the section that separates this page from every other sermorelin page you will read.
The approved product, Geref, was a subcutaneous injection. Every meaningful clinical study of sermorelin used an injected route. There is no published human pharmacokinetic or clinical trial data establishing that an oral dissolving tablet delivers comparable exposure, or establishing what exposure it delivers at all.
That is not a small caveat. Peptides of this size are poorly absorbed across oral mucosa and are broken down rapidly in the gastrointestinal tract — that biology is why injectable delivery dominates peptide medicine generally. A dissolving format is designed to work around it. Whether it succeeds, for sermorelin, is not something the published literature currently answers.
So why do we offer it? Because the alternative to a needle-free option, for a meaningful number of people, is nothing. A treatment someone will not take has an efficacy of zero regardless of its bioavailability. If you have decided you are not going to inject, and you understand what is and isn't established about this route, then the tablet is a reasonable thing to try under monitoring — and monitoring is exactly how you find out whether it is doing anything for you, which is a better question than what it does on average.
What we will not do is tell you the tablet is equivalent to an injection. We do not know that, nobody does, and the confident claims you will find elsewhere are marketing.
What we will not claim
Being explicit about this is part of the service.
It is not an anti-aging treatment. We do not make that claim and we do not use that language. Sermorelin is not growth hormone, and the marketing conventions this category borrowed are not ones we are going to borrow.
It will not do what injected growth hormone does. It cannot, by design. Anyone selling it as growth hormone without the prescription is selling you a misunderstanding.
It does not treat a diagnosed growth hormone deficiency in adults in our hands. That is a specialist endocrine diagnosis requiring stimulation testing and specialist management, and if your workup points that way we will refer you rather than treat you.
There is no timeline we can promise. Sleep changes, where they occur, are usually reported earliest. Anything to do with body composition is a matter of months and is inseparable from training and nutrition.
Two different evidence questions
Sermorelin as a molecule has a longer track record than most of the peptide category — decades of use, an approval history, and a mechanism that is well understood. That puts it in a different tier from the compounds with mostly preclinical support.
The oral dissolving tablet route does not inherit that track record. It is a delivery format applied to a well-characterized molecule, without published data establishing that the format works. Those are two different evidence questions and we think you should be told which one you are buying into.
This is also why monitoring is not optional here. Your clinician establishes a baseline before you start and reviews it on a defined cadence, so that the question "is this doing anything for me" gets an answer from your labs and your reported experience rather than from hope. If it isn't, we stop. A provider who never stops anything is not monitoring.
ODT, injection and growth hormone are not the same thing
ACT 2 Health offers sermorelin as an oral dissolving tablet only. The injection column below is context, not a menu item — it is the route the original clinical work used, and it is the reason the evidence question on this page exists at all. Growth hormone is a different medication entirely.
The trade-off, stated plainly: the injected route is the one with the published evidence behind it, and the tablet is the one that someone who will not inject will actually take. Which of those matters more in your case is a clinical conversation, and it is one worth having out loud rather than around.
How the tablet is taken
A tablet that dissolves in the mouth rather than an injection, taken as directed by your clinician. We do not publish dosing information for any medication — that is a clinical decision made for you individually after eligibility review, not something to read on a website.
Who this route suits
Adults in their 40s, 50s and beyond who are noticing changes in sleep quality, recovery and body composition, who have had those changes properly worked up rather than assumed, and who have decided against injectable options. It comes up most often with active adults and former athletes whose recovery no longer matches their training, and with professionals whose sleep debt has stopped clearing on a weekend. It is a poor fit if you are looking for a dramatic or rapid change, if you have not had baseline labs, or if your symptoms have an unexamined cause — fatigue in midlife has a long differential, including thyroid, iron, sleep apnea, hormonal change, depression and medication effects, and most of it is cheaper and more treatable than a peptide.
Who it isn't for
Sermorelin is not appropriate for everyone, and eligibility is a clinical decision made after review, not a checkbox. Your clinician will go through your full history, including any history of malignancy, any pituitary condition, current medications, and pregnancy or breastfeeding. Some histories make this a clear no. Others make it a "not until we've looked at something else first."
The cancer question is the one people most often want a straight answer to, and it deserves more room than a line here. We answer it in full in sermorelin, IGF-1 and cancer risk.
Why the needle question deserves a straight answer
Providers tend to treat injection reluctance as an objection to be handled. It usually isn't. It is a real constraint, and it comes from real places: a genuine needle phobia, a job or travel pattern that makes a refrigerated injectable impractical, a household where injections are not something you want to explain, or simply a considered preference that you have every right to hold without being talked out of it.
The reason this matters clinically as well as commercially is that the alternative to acknowledging it is a patient who agrees to an injectable in the room and quietly stops three weeks later. Adherence is not a footnote to efficacy — for anything taken over months, it is most of it.
So the framing we use is this: the injected route has the evidence behind it, the tablet has the adherence advantage for people who will not inject, and the right answer is the one you will actually take, chosen with the trade-off stated out loud rather than hidden.
What happens if it isn't working
This is the question the category avoids, so we will answer it.
Because this route has no established pharmacokinetics, the only meaningful evidence about whether it is doing something is your evidence — your labs and your reported experience, reviewed against your own baseline on a defined schedule. That is a lower bar than a clinical trial and a much higher bar than a testimonial.
If the review shows nothing is moving, there are three honest options and your clinician will put all three on the table: change the route, change the target, or stop. Stopping is a legitimate outcome and it is one we reach with patients. What we will not do is keep you on a compounded medication indefinitely on the theory that it might be working quietly.
Where this fits in your plan
Start with measurement. A Comprehensive Lab Panel is the prerequisite, not an upsell — most of the symptoms that bring people to this page have explanations that show up on a panel. If you want the broader context on how peptides work and where they fit, the peptide therapy pillar is the place to start. If sleep and recovery are the driver, it is worth reading the athletes and executives hubs, which deal with the underlying causes before the treatments.
Current pricing is on our pricing page, and where we are licensed is on states we serve.
Clinicians who focus on longevity
Your visit is with a licensed clinician in your state. These are the members of the medical team whose practice centers on longevity; who you see depends on your state and availability.
Medical services are provided by licensed clinicians practicing through an independent professional entity.
Often considered alongside
NAD+ Injection
CompoundedA coenzyme central to cellular energy, explored to support energy and recovery in midlife.
View treatmentB12 Injection
A vitamin B12 injection explored for energy support, often used within a broader plan.
View treatmentBPC-157
CompoundedThe recovery peptide people ask about most, prescribed through a clinician-led program with baseline labs, a licensed U.S. pharmacy and a published monthly price.
View treatmentProducts marked Compounded are prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved and are not equivalent to or interchangeable with any branded product.
Sermorelin ODT, question by question
The specific questions people bring to this treatment, each answered on its own page and reviewed the same way this one is.
Sermorelin, IGF-1 and Cancer Risk: The Honest Position
Higher IGF-1 is linked to several cancers in large studies. Sermorelin raises IGF-1. What is known, and why active cancer is an absolute exclusion.
ReadSermorelin and Sleep: The Slow-Wave Connection
Growth hormone and deep sleep are released together and decline together. What GHRH studies showed, and why we screen sleep before prescribing sermorelin.
ReadIGF-1 on Sermorelin: What the Number Means
IGF-1 is the blood test that shows whether sermorelin is doing anything. Why it stands in for growth hormone, and what a rise does and does not tell you.
Read
An honest word on the evidence
Sermorelin the molecule has a longer track record than most of the peptide category — decades of use, an approval history, and a mechanism that is well understood. The oral dissolving tablet route does not inherit that record: every meaningful clinical study of sermorelin used an injected route, and there is no published human data establishing what a dissolving tablet delivers. Those are two different evidence questions, and this page answers both rather than blurring them. It is also why monitoring is not optional here — your baseline and your reviews are the only real evidence about whether this route is doing anything for you, and if nothing is moving, we stop.
References
Government and professional-society sources consulted for this page.
- Compounding and the FDA: Questions and Answers — U.S. Food and Drug Administration
Frequently asked questions
Growth hormone supplies the hormone directly and overrides your body's own control of it. Sermorelin signals your pituitary to release more of the growth hormone you already make, so your own feedback regulation stays intact. The practical consequence is that the effect is more modest and more variable than injected growth hormone — that is the design, not a shortcoming.
We can't tell you that, and we won't. Every clinical study of sermorelin used an injected route, and there is no published human data establishing what an oral dissolving tablet delivers. What we can tell you is that peptides of this size are poorly absorbed through the gut and across oral mucosa, that the dissolving format is designed to address that, and that whether it succeeds is not established in the literature. The injected route is the one with the published evidence behind it. ACT 2 Health offers sermorelin only as an oral dissolving tablet, so that trade-off is worth raising with your clinician when you decide whether this therapy is right for you at all.
Because a treatment you won't take doesn't work either. For someone who has decided against injections, a monitored trial of the needle-free route — with the uncertainty stated up front and a real stopping point — is a reasonable option. What makes it reasonable is the monitoring, not the tablet.
Not in the form sold today. Sermorelin was FDA-approved in 1997 as Geref for growth hormone deficiency in children, and was discontinued in the United States in 2008 for commercial rather than safety reasons. It is now available only as a compounded medication, and compounded medications are not FDA-approved.
Sermorelin was not among the twelve peptide substances the FDA removed from Category 2 of its interim 503A bulks list in April 2026, and it is not in the same regulatory position as the compounds that were restricted. Peptide regulation is actively changing, and we will update this page as it does.
As an oral dissolving tablet, taken as directed by your clinician. We do not publish dosing information for any medication — that is a clinical decision made for you individually after eligibility review, not something to read on a website.
There is no timeline we can promise, particularly for this route. Where changes are reported, sleep quality tends to be reported earliest. Anything to do with body composition is a matter of months and is not separable from training and protein intake.
Yes. Baseline labs are a prerequisite, and they are also the most likely thing to change your plan — a good number of people who come in asking about peptides leave with something else, because the panel found the actual explanation.
Your clinician reviews response on a defined cadence and will tell you plainly. The options are to change the route, change the target, or stop, and stopping is a real one.
See if Sermorelin ODT fits your plan
The right plan begins with knowing where you are. Start with a short eligibility check and a baseline — and we'll tell you, honestly, what fits.
We measure first. Then we act.
ACT 2 Health provides clinician-led care. Treatments described are available only to eligible patients following clinical evaluation and within applicable regulations. This page is educational and is not medical advice. Individual results vary.